Payers

Anxiety Gets a Psychedelic Trial, Not a Shortcut

AI Wants to Choose Pancreatic Chemo

The first oral PCSK9 inhibitor is approved. A pill will not fix cholesterol access by itself

Oral GLP-1 drugs could widen access, but high prices may do the opposite

GLP-1 drugs can reduce adolescent obesity. Who will pay for years of treatment?

Boehringer Ingelheim is adding a third target to obesity treatment.

The weight came back. Some visceral fat did not. Obesity care may be measuring the wrong outcome

China Just Put a Bispecific ADC Into Esophageal Cancer

The Novo Nordisk Foundation is going global on cardiometabolic disease.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
